Detection of bone metastases in urogenital malignancies utilizing 99mTc-labeled phosphate compounds.
A retrospective study of 99 patients with proved urogenital malignancies was done to determine the value of bone scanning versus roentgenographic skeletal survey in assessing the degree of metastatic involvement. Findings on bone scans were positive in 59 patients, and in 7 of these patients results of roentgenographic skeletal survey were negative; 11 additional patients had only minimal roentgenographic abnormalities in contrast to more extensive involvement demonstrated by bone scanning.